Solid Biosciences Files Prospectus for $85 Million Offering

Solid Biosciences ( (SLDB) ) has issued an update.

On May 15, 2025, Solid Biosciences Inc. filed a prospectus supplement with the SEC, allowing for the offer and sale of up to $85 million of its common stock, following a previous prospectus for $75 million. As of the filing date, the company had raised approximately $10.5 million, and will cease offers under the prior prospectus.

The most recent analyst rating on (SLDB) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Solid Biosciences stock, see the SLDB Stock Forecast page.

Spark’s Take on SLDB Stock

According to Spark, TipRanks’ AI Analyst, SLDB is a Neutral.

Solid Biosciences’ stock score reflects significant financial struggles, with no revenue generation and ongoing losses. The technical analysis presents a mixed view, with indicators suggesting potential overbought conditions despite limited momentum. The valuation is unattractive due to negative earnings and lack of investor returns. Overall, the company’s financial challenges are the most significant factor impacting its stock performance.

To see Spark’s full report on SLDB stock, click here.

More about Solid Biosciences

Solid Biosciences Inc. operates in the biotechnology industry, focusing on developing innovative treatments for genetic disorders, particularly Duchenne muscular dystrophy.

Average Trading Volume: 2,869,298

Technical Sentiment Signal: Sell

Current Market Cap: $216.2M

Find detailed analytics on SLDB stock on TipRanks’ Stock Analysis page.